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Abstract Because of its ability to integrate chromosomally and 
its non-pathogenic nature, adeno-associated virus (AAV) has 
significant potential as a human gene therapy vector. Here we 
investigate the maximum amount of DNA which can be inserted 
into the AAV genome and still allow efficient packaging into an 
infectious virus particle. Altered wild-type AAV genomes were 
constructed with inserts, which increased in size by 100 bp, 
ligated at map unit 96. These large wild-type-plus genomes were 
able to replicate and produce infectious virus, at levels slightly 
reduced but comparable to normal sized wild type, until the insert 
size reached 1 kb. These data indicate that the maximum 
effective packaging capacity of AAV is approximately 900 bp 
larger than wild type, or 119%. Furthermore, it is demonstrated 
that these large AAV genomes are able to latently infect cells by 
chromosomal integration as does wild-type AAV. These data 
suggest that therapy vectors carrying a foreign gene of 900 bp or 
less can be generated from AAV, by ligation into non-essential 
locations, and result in a recombinant AAV virus with a fully 
wild-type phenotype. Such wild-type-plus AAV vectors will have 
both advantages and disadvantages over defective recombinant 
AAV virus — the most important advantages being the ease in 
which high titers of infectious virus can be generated and the 
ability to specifically integrate within chromosome 19. Once the 
concern subsides over the presence of wild-type AAV in clinical 
applications, wild-type AAV vectors may find specific applica-
tion niches for use in human gene therapy. 
© 1997 Federation of European Biochemical Societies. 
Key words: Adeno-associated virus; Gene therapy; 
Packaging capacity 
1. Introduction 
Adeno-associated virus (AAV) is a helper-dependent human 
parvovirus which is able latently to infect cells by chromoso-
mal integration. Various studies, from 1970 to 1986, demon-
strated that 15-30% of immortalized cells could be latently 
infected with wild-type AAV and that the AAV genome was 
chromosomally linked [1-3]. After the mapping of AAV genes 
and their functions [4,5], a similar ability was demonstrated 
for recombinant AAV in 1984 in immortalized tissue culture 
cells [6,7], and in 1988 recombinant AAV transduction of 
primary hematopoietic stem cells was achieved [8]. More re-
cently, in 1990, the preferred site of wild-type AAV integra-
tion was demonstrated to be in a region of human chromo-
some 19 [9-11]. Many laboratories have confirmed and 
extended these data and demonstrated the utility of AAV-
based vectors [12-18]. In the last year the likely initiation of 
the deciphering of the mechanism of wild-type AAV integra-
tion has begun with the finding that a complex between chro-
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mosome 19 DNA and AAV terminal repeat DNA was formed 
in the presence of the AAV Rep78/68 protein [19-21], the 
same protein which is required for AAV DNA replication 
[4,5]. 
AAV's largest disadvantage as a gene therapy vector may 
be its limited packaging capacity, dictated by the limited size 
of the AAV virion. Additional disadvantages of recombinant 
AAV as gene therapy vectors include the difficulty in the 
producing of high virus titers and their inability, because 
they lack the rep gene (Rep78/68), to target integration into 
chromosome 19. In this study all of these problems are ad-
dressed. To address AAV's packaging capacity large wild-type 
AAV genomes, which increase in size in steps of 100 bp, were 
utilized to investigate AAV's maximum capacity. It is demon-
strated that genomes larger than wild type by 900 bp, or 
119%, have a fully wild-type phenotype, including chromo-
some 19 integration. Thus, genes of significant size might be 
inserted into AAV and still result in a phenotypically wild-
type virus. These findings also address the liter and specific 
integration problems as the use of wild-type AAV vectors 
would circumvent both of these limitations of recombinant, 
defective AAV vectors. 
2. Material and methods 
2.1. Cells and plasmids 
FfeLa, SW13, and D510 (Detroit 510) cells were grown in Delbec-
co's Modified Eagles Medium with 7% fetal bovine serum plus pen-
icillin and streptomycin. The construction scheme of ins96-Ä,-R, ins96-
X.-M, and ins96-À-F has been described previously [6]. Briefly, to gen-
erate these plasmids random Sau3Al fragments from X phage were 
ligated into the Bgttl site of ins96. Ins96-A.-R, ins96-Ä.-M, and ins 96-
X-F have insets of 0.5, 1.1 and 2.8 kb, respectively. To generate the 
100 bp stepped large AAV plasmids '100 bp DNA ladder' marker 
DNA was purchased from Gibco BRL (catalog #15628), agarose 
gel electrophoresed, and the 600, 700, 800, 900, and 1000 bp frag-
ments were cut out of the gel, and isolated by the Quiex DNA iso-
lation kit (Qiagen). Each of the isolated fragments was ligated into the 
Sg/II site of ins96 [4] using BamHl linkers to generate ins96+0.6, 
ins96+0.7, ins96+0.8, ins96+0.9, and ins96+1.0. 
2.2. DNA replication and virus production 
The AAV genomes were assayed for their ability to generate infec-
tious virus using a sequential, two plate, Southern blot analysis [4-6]. 
After AAV plasmid transfection plus Ad infection, half of the cells 
from the first plate are assayed for DNA replication by Southern blot. 
The medium and the other half of cells from the first plate (now a 
potential virus stock) are then added to a second plate to assay for 
virus infection and DNA replication, again by Southern blot analysis. 
AAV constructs which are unable to produce infectious virus, such as 
capsid (cap) mutant ins63, are unable to survive and replicate in the 
second plate [[4—6], and Fig. 2]. In more detail, 1 ug of AAV plasmid 
was DEAE/dextran transfected into the indicate cells (10 cm plate at 
80% confluence) as described previously [6]. The cells were then in-
fected with adenovirus type 2 at an multiplicity of infection (MOI) of 
5. At 36^48 h later one-half of the cells was lifted off the plate by a 
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rubber policeman and the cells and medium were removed. The re-
maining cells (first plate) were analyzed by low molecular weight Hirt 
DNA extraction [26], and Southern blot analysis (10% of DNA iso-
lated)[27], probing with 32P-labeled AAV DNA or 32P-100 bp ladder 
DNA as indicated to observe viral replication. The half cells scrapped 
off and left in suspension in DMEM (10 ml) were freeze/thawed 
3 times, heated to 56°C for 30 min (to kill Ad), and one-third 
(33%) of the suspension (potential virus stock) was then added to a 
second plate of tissue culture cells which were subsequently infected 
with Ad2 at an MOI of 5. At 36-48 h the second plate of cells were 
Hirt DNA extracted (virus production). 10%o of the extracted DNA 
from both the first and second plates were agarose gel electrophor-
esed, Southern blotted, and probed with 32P-labeled AAV DNA or 
32P-100 bp ladder DNA probe, 'dsm' indicates double-stranded 
monomer DNA, and 'ssm' indicates single-stranded monomer length 
DNA. 
2.3. Construction of latently infected cells 
103 HeLa or D510 cells was infected with 106 infectious units of 
ins96+0.9 virus. The cell cultures were then grown for 4-5 weeks, with 
at least three cell splits/replatings. 
2.4. PCR amplification and dot-blot hybridization analysis 
Two different PCR procedures, amplifying either the AAV rep gene 
or the AAV TR-chromosome 19 SI junction, were performed on 
DNA from the indicated D510 cells. PCR amplification and dot-
blot hybridization analysis for AAV rep sequences has been described 
[28]. The primers for PCR amplification of an AAV TR-human chro-
mosome 19 junction have been described [10]. Each PCR reaction 
contained between 1 ug of total DNA isolated from the indicated 
cell. The reaction buffer, with and without pSM620 (cloned wild-
type AAV, 1 pg pSM620 in 1 |xg of HeLa cell genomic DNA), served 
as the positive and negative controls, respectively, for the AAV rep 
amplifications. One-tenth volume of the PCR product was then dena-
tured, fixed to a nylon membrane and hybridized with the appropriate 
internal 32P-probe (sequences located between the two primers). The 
AAV-human chromosome 19 junction product was probed and iden-
tified using two different probes. One probe, used in Fig. 7C, was of 
sequences of the AAV terminal repeat, from nt 95-125. The other 
probe, used in Fig. 7D, was of human chromosome 19 sequences 
upstream of, but not overlapping with, the chromosome 19 side 
PCR primer (5'-ACTCCAATGCGGAAGAGAGTAGGTCG). 
3. Results 
3.1. Large AAV genomes with insertions of 1.1 kb and larger 
are severely defective for producing infectious virus 
To investigate the packaging capacity of AAV, various 
large AAV genomes were assayed for their ability to generate 
infectious virus. The location of the D N A insertions is shown 
in Fig. 1. F o r one series of large AAV genomes, SauiAI frag-
ments from bacteriophage X were ligated into the BgUI site of 
Fig. 1. Structure and Pstl map of the large AAV genomes. The 
phenotypic map of AAV is shown. At the top are indicated the re-
gions attributed to the four major phenotypes (TRIori, rep, lip, cap) 
labeled [4]. Also indicated is the position, a Bg/II site at map unit 
96, into which foreign DNA was ligated to generate the larger than 
wild-type AAV vectors. Heterologous DNA was inserted here be-
cause no eis or trans elements are located here. Below is shown the 
Pstl restriction sites within the cloned AAV plasmid ins96 from 
which the larger than wild-type AAV vectors were generated, and 
the resulting fragment sizes. 
Fig. 2. Genetically wild-type AAV genomes with inserts of 1.1 kb 
and larger are severely defective for producing infection virus. Vari-
ous AAV genomes were assayed for their ability to generate infec-
tious virus. Shown is a sequential, two plate Southern blot analysis 
as described in detail in Section 2 (The first plate assays for DNA 
replication by Southern blot.) Materials from the first plate, a po-
tential virus stock, are then added to the second plate. Thus, South-
ern blot analysis of the second plate assays for virus infection and 
DNA replication. The probe was 32P-labeled AAV DNA. Note that 
wild-type pSM620 is able to generate infectious virus which is able 
to infect and replicate in the second plate. In contrast, ins63, a cap 
mutant, is unable to produce infectious virus in the first plate and is 
unable survive to replicate in the second plate. Also note the ins96-
X-R (+0.5 kb) is able produce infectious virus, while ins96-VM 
(+1.1 kb) and ins96-Ä.-F (+2.8 kb) are defective in virus production. 
As these genomes are genetically wild type the inability to produce 
infectious virus is likely due to the increase in genome size. No cap 
mutant has ever been found to survive and replicate in the second 
plate. 
ins96 to generate a series of large AAV genomes [6]. As no eis 
or trans elements are located at map unit 96, thus these large 
AAV genomes are genetically wild-type and are simply larger 
than normal size. Three resulting clones, ins96-X-R (+0.5 kb), 
ins96-?i-M (+1.1 kb), and ins96-?i-F (+2.8 kb), were used for 
analyzing the packaging capacity. These large AAV genomes 
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Fig. 3. Pstl restriction analysis of the large AAV genomic plasmids. 
Shown is a Pstl restriction analysis of the plasmid DNA of larger 
than wild-type AAV cloned genomes. One ug of each of the indi-
cated AAV plasmids was analyzed by Pstl digestion, agarose gel 
electrophoresis, and ethidium bromide staining. The Pstl sites of the 
AAV genomes and plasmids are shown in Fig. 1. Note that the 
Pstl DNA fragment containing the right AAV TR increases in size 
with the increasing size of the DNA insertion. Originally the right 
TR Pstl fragment was 0.45 kb in size as shown in the pSM620 di-
gestion (fully wild-type AAV). These altered Pstl fragments increase 
in size by 0.6-1.0 kb depending upon the size of the DNA ligated 
into the BgR\ site at map unit 96. 
vive to replicate in the second plate. No AAV cap mutant has 
been found to survive and replicate in the second plate of this 
assay [4,6]. Of the large AAV genomes, Ins96-Ä,-R (+0.5 kb) 
was found to be able to produce infectious virus, and at a 
level comparable with wild-type pSM620. In contrast, both 
ins96-A,-M (+1.1 kb) and ins96-A,-F (+2.8 kb) were severely 
defective in virus production. As these genomes are genetically 
wild type, the inability to produce infectious virus are likely 
due to the increase in genome size. However, on long expo-
sure a small amount of ins96-A,-M was found to be replicating 
in the second plate (about 0.1% of wild type) indicating that it 
was packaged at a very low level. In several experiments 
ins96-?i-F was never found to replicate in the second plate. 
In this particular experiment pSM620 replicated slightly better 
in the first plate than the large ins96-based AAV genomes. 
This difference is due to experimental variability and is not 
seen in other similar experiments (e.g. Fig. 5) These data in-
dicate that the maximum efficient packaging capacity for the 
were then compared to wild-type AAV (pSM620 [22] and 
ins63 [4]. Ins63 is an 8 bp BgR\ linker insertion frame shift 
mutant at map unit 63, within the capsid gene {cap), and is 
able to replicate (rep+), but unable to produce infectious virus 
(cap-). 
A sequential, two plate Southern blot analysis [4-6] was 
used to observe virus production, shown in Fig. 2 (described 
in detail in Section 2). To carry out this analysis the AAV 
genomes, as plasmids, were DEAE/dextran transfected into an 
initial, first plate of Ad-infected HeLa cells. At 2 days post-
transfection low molecular weight Hirt DNA was isolated 
from half the cells, then 10% of the DNA was gel electro-
phoresed, Southern blotted, and probed for AAV sequences 
(top of figure). The second half of the cells plus the medium, 
now a potential AAV virus stock, was used to infect a second 
plate of Ad-infected cells. At 2 days post-infection low mo-
lecular weight Hirt DNA was isolated from second plate, then 
10% of the DNA was gel electrophoresed, Southern blotted, 
and probed with 32P-labeled AAV sequences (bottom of Fig. 
2). 
As shown in Fig. 2, as expected, wild-type AAV, pSM620, 
was able to generate virus in the first plate and infect and 
replicate in the second plate (bottom of Fig. 2). In contrast, 
the cap mutant ins63 was able to replicate its DNA in the first 
plate, but was unable to produce infectious virus and to sur-
Fig. 4. Ins96+1.0 is packaged at a lower efficiency than smaller ge-
nomes in HeLa cells. Shown is a sequential, two plate Southern 
blot analysis for infectious virus production, similar to that de-
scribed in Fig. 2. In this experiment, however, the stepped 100 bp 
large AAV genomes are analyzed and 32P-labeled 100 bp ladder [in-
sert] probe) is used to score for replicating AAV DNA. Note that 
all the AAV plasmids were able to replicate in the first plate; how-
ever, in the second plate ins96+1.0 was defective infectious virus 
production and subsequent DNA replication, when compared to the 
slightly smaller AAV genomes. These data indicate that the maxi-
mum packaging capacity of the AAV virion was exceeded by 
ins96+1.0. 'dsm' indicates double-stranded monomer DNA, and 
'ssm' indicates single-stranded monomer length DNA. 
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Fig. 5. Ins96+1.0 is packaged at a lower efficiency than smaller ge-
nomes in SW13 cells. Shown is a sequential, two plate Southern 
blot analysis for infectious virus production, similar to that de-
scribed in Figs. 2 and 4. In this experiment, however, the stepped 
100 bp large AAV genomes are analyzed in SW13 cells and 32P-la-
beled AAV DNA is used to score for replicating AAV DNA. Note 
that all the AAV plasmids were able to replicate in the first plate; 
however ins96+1.0 was significantly reduced for significant replica-
tion (could not effectively produce infectious virus) in the second 
plate. Ins96+0.9 was at 70.5 ±32%, and ins96+1.0 at 25.7 ±16.2%, 
the level of pSM620 in the second plate as determined by densito-
metric analysis in three experiments. There are a few faint bands in 
the ins96-Ä.-M and null lanes of the second plate analysis. These are 
high non-specific bands, probably due to contaminating high molec-
ular weight genomic DNA and incomplete washing of the mem-
brane. These bands were not observed in any of the redundant ex-
periments. With Fig. 4, these data indicate that the maximum 
packaging capacity of the AAV virion was exceeded by ins96+1.0. 
'dsm' indicates double-stranded monomer DNA, and 'ssm' indicates 
single-stranded monomer length DNA. 
compasses the right AAV terminal region of AAV with the 
BgUl restriction site at nt 4484 (map unit 96). This fragment 
increased in size in constructs ins96+0.5 to ins96+1.0, corre-
sponding to the size of the 600-1000 bp fragment which was 
ligated into it (Fig. 3). 
The series of stepped 100 bp ins96 genomes were then an-
alyzed in the sequential 2 plate assay for virus production. 
Both HeLa and SW13 cells were used in this analysis. As 
shown in the top (first plate) of Fig. 4, using Hela cells and 
using the 100 bp DNA ladder DNA as 32P-labeled probe, all 
of the large ins96 genomes were able to replicate at compara-
ble levels. As shown in the top (first plate) of Fig. 5, using 
SW13 cells and using total AAV DNA as 32P-labeled probe, 
all of the large ins96 genomes were able to replicate at com-
parable levels to unaltered wild-type AAV, pSM620. In Fig. 6, 
to better observe the size differences of the AAV genomes the 
replicating DNAs from the same Hirt DNAs of Fig. 3 were 
further analyzed by Southern blot analysis after Pstl digestion 
(32P-labeled 100 bp ladder marker DNA as probe). As can be 
seen the there is a corresponding, ascending increase in size of 
the replicated DNA comparable to increase in size of the 
inserted DNA. No smaller, deleted, Pstl fragments are ob-
served below the full-length bands indicating that significant 
deletions of the 100 bp marker DNA inserts are not taking 
place. 
In contrast to near equal replicating abilities in the first 
plate, differences became apparent for one mutant, 
ins96+1.0, in its ability to produce infectious virus. As shown 
in the bottom of Figs. 4 and 5 (bottom, second plate), the 
large AAV genomes ins96+0.6, ins96+0.7, ins95+0.8, and 
AAV virion was somewhere between 0.5 and 1.1 kb larger 
than wild type (4.7 kb). 
3.2. A 900 base insertion is the maximum size allowable for 
near wild-type packaging efficiency 
To more accurately define the packaging capacity of the 
AAV virion another series of large, genetically wild-type 
AAV genomes were constructed (see Section 2 details). These 
large AAV genomes increased sequentially in size by 100 bp. 
The inserted fragments originated from the Gibco BRL 100 
bp DNA size marker, and were ligated into the Bglll site of 
ins96 via BamHl linkers. The ligated fragments ranged in size 
from 600 to 1000 bp and this resulted in the cloned AAV 
plasmids, ins96+0.6, ins96+0.7, ins96+0.8, ins96+0.9, and 
ins96+1.0 with the insert size indicated within the correspond-
ingly named AAV plasmid. An agarose gel analysis of these 
plasmids, analyzed by Pstl digestion, is shown in Fig. 3. As 
shown in Fig. 1, the smallest Pstl fragment (~0.45 kb) en-
Fig. 6. Size analysis of the replicating DNA of the large AAV ge-
nomes. Shown is a Pstl restriction analysis of replicating (Hirt) 
DNA from the first plate of Fig. 4. After digestion the DNA was 
Southern blotted and probed with 32P-labeled 100 bp ladder DNA. 
With this probe only the altered right Pstl fragment is viewed. Indi-
cated are the monomer and dimer (from tail-to-tail dimers) size left 
Pstl fragments which contain the inserts. Note that the Pstl frag-
ments increase in size corresponding to the size of the insert, with 
ins96+0.6 giving the smallest, and ins96+1.0 giving the largest sized 
products. Also note that deleted fragments are not visible. This indi-
cates that recombination and elimination of the 100 bp repeats is 
not taking place at significant levels. 
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B Fig. 7. Latent infection and chromosome 19 integration the ins96+0.9 virus genome. A: Southern blot analysis of Ad2 rescue of 
HeLa cells latently infected with ins96+0.9 virus 4 weeks previous. 
B: PCR amplification/dot-blot analysis for AAV rep DNA sequen-
ces from D510 cells latently infected with ins96+0.9 virus 4 weeks 
previous. C: PCR amplification/dot-blot analysis for AAV-chromo-
some 19 junction DNA sequences from D510 cells latently infected 
with ins96+0.9 virus 4 weeks previous. In more detail: A: Southern 
blot demonstrating the rescue of ins96+0.9 from latently infected 
HeLa cells. One thousand HeLa cells were infected with 106 infec-
tious units of ins96+0.9 virus. The cells were grown and passed for 
4 weeks upon which time the cells were infected with Ad2 and 48 h 
later a Hirt DNA extraction was carried out. One-third of the ex-
tracted DNA was agarose gel electrophoresed, Southern blotted, 
and probed with 32P-labeled 100 bp marker DNA. Note that a sig-
nificant level of replicating ins96+0.9 DNA is observed indicating a 
significant level of latent infection by this virus. B: D510 cells were 
latently infected with ins96+0.9 virus as in (A). Total cellular DNA 
was isolated. One microgram of the cellular DNA was used for 
PCR amplification with primers designed to amplify part of the 
AAV rep gene (24). One-tenth of the PCR product was then dot-
blotted and probed using a sequence located between the two pri-
mers. Note that a significant signal is present in the 
D510+ins96+0.9 well. C: Demonstration of ins96+0.9 specific inte-
gration into chromosome 19 SI sequences by PCR amplification of 
the AAV TR-human chromosome 19 junction sequences probed 
with an internal AAV TR sequence. One microgram of the cellular 
DNA from (B) was used for PCR amplification with primers de-
signed to amplify the AAV-chromosome 19 junction within the pre-
fered site of AAV integration (9). One-tenth of the PCR product 
was then dot-blotted and probed using an AAV TR sequence lo-
cated between the primers. Note that a significant signal is present 
in the D510+ins96+0.9 well indicating chromosome 19 integration. 
D: Demonstration of ins96+0.9 specific integration into chromo-
some 19 SI sequences by PCR amplification of the AAV TR-hu-
man chromosome 19 junction sequences probed with an internal 
chromosome 19 sequence. This experiment was carried out similar 
to (C), except that the dot-blot was probed with a chromosome 19 
sequence 5', internal, of the chromosome 19 junction primer. Note 
that a significant signal is present in the D510+ins96+0.9 well indi-
cating chromosome 19 integration. 
ins96+0.9 were able to effectively produce virus as judged by 
their DNA replication in the second plate. In contrast, 
ins96+1.0 was significantly lower in virus production, in 
both HeLa and SW13 cells. In three experiments ins96+0.9 
was at 70.5 ± 32%, and ins96+1.0 at 25.7 ± 16.2%, the level of 
pSM620 in the second plate as determined by densitometric 
analysis. Ins96-A,-M was again shown to be very inefficient in 
generating infectious virus (as in Fig. 2). However, again, 
upon very long exposure it was observed that ins96-A,-M did 
often produce low levels of infectious virus (estimated to be 
~ 0.1-1% that of wild type). From these data it was deter-
mined that genomes 0.9 kb larger than wild type were able to 
be packaged into infectious AAV virus particles at levels only 
slightly depressed compared to wild type. 
3.3. Infectious ins96+0.9 kb virus are able to latently infect 
cells by chromosome 19 SI integration 
We next assessed if these large AAV genomes were able to 
latently infect cells by chromosomal integration as does fully 
wild-type AAV. To determine if this was the case 103 HeLa 
cells were infected with ins96+0.9 virus stock. The cells were 
grown to confluence, then passed three times after 1:10 splits. 
After 4 weeks of continuous growth the HeLa/ins96+0.9 cells 
were then infected with adenovirus to rescue any chromoso-
mally integrated ins96+0.9 genomes. The Southern blot anal-
ysis of Hirt DNA using 32P-labeled 100 bp marker probe of 
Hirt DNA from these cells is shown in Fig. 7A. A significant 
level of replicating ins96+0.9 DNA is seen. Although these 
data do not directly demonstrate that the ins96+0.9 genome 
is chromosomally integrated, after 4 weeks of cell growth it is 
likely that no significant level of episomal AAV DNA would 
survive out to this time. The demonstration of significant 
ins96+0.9 replicating DNA after Ad2 infection suggests that 
considerable levels of chromosomal integration have taken 
place. 
To demonstrate that the ins96+0.9 virus was specifically 
integrated into human chromosome 19, 103 D510 cells were 
infected with ins96+0.9 virus stock. The cells were grown to 
confluence, then passed 3 times after 1:10 splits. After over 
4 weeks of continuous growth genomic DNA was isolated and 
analyzed by PCR amplification/dot-blot hybridization by two 
procedures. First, shown in Fig. 7B, PCR amplification and 
hybridization for AAV rep sequences were carried out. The 
D510 cells latently infected with ins96+0.9 virus gave a very 
strong signal. These data are consistent with significant AAV 
being present, most likely integrated. However these data do 
not conclusively indicate specific chromosome 19 SI integra-
tion. As a selectable marker gene is not present within 
ins96+0.9 it was not possible to observe chromosomal inte-
gration by Southern blot analysis of genomic DNA. Next, to 
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demonstrate chromosome 19 SI-specific integration, PCR am-
plification of the AAV TR-chromosome 19 junction sequen-
ces was carried out, as shown in Fig. 7C,D. The chromosome 
19 SI-side primer is of sequences located at the preferred site 
of AAV integration [10]. The AAV-chromosome 19 junction 
PCR amplification product was identified by two different 
probes in dot hybridization assays. One 32P-labeled probe, 
used in Fig. 7C, was of an AAV TR sequence which was 
internal to the upstream AAV TR amplification primer. An-
other 32P-labeled probe, used in Fig. 7D, was of a chromo-
some 19 sequence which was internal to the chromosome 19 
amplification primer. Upon using both probes, the PCR am-
plified DNA from the D510 cells latently infected with 
ins96+0.9 virus gave a positive signal (Fig. 7C,D). As this 
PCR amplification is based on one primer of AAV TR se-
quences and the other of human chromosome 19 SI sequen-
ces, these data unambiguously indicate a direct, covalent link-
age between the AAV and chromosome 19 SI sequences. 
4. Discussion 
In this study we demonstrate that the AAV virus particle is 
able to accommodate 900 additional nucleotides above wild-
type size (119%) with reasonable efficiency. This size repre-
sents a maximum limit for the construction of recombinant 
AAV vectors. Furthermore, this study raises the feasibility of 
constructing and using wild-type-plus AAV vectors for gene 
therapy purposes. Genes of 900 bases or less can be inserted 
into AAV and still allow the resulting vector to have a largely 
wild-type phenotype. For example, several antisense genes 
could be inserted and still allow packaging. In preliminary 
data we have inserted the Neomycin resistance gene (Ned) 
coding sequence into AAV at map unit 96. Recombinant 
ins96-0.9Neo virus are able transduce HeLa cells and confer 
G418 resistance even though the Neo gene does not have a 
dedicated promoter (Hermonat and Han, unpublished). Such 
wild-type vectors would have several advantages or disadvan-
tages. First, high titers of such vectors should be easy to 
accomplish. Second, the vectors, since they include the 
Rep78 gene, would integrate specifically into human chromo-
some 19. Third, such vectors, being phenotypically wild type, 
have a potential to spread after their initial introduction. The 
ability for such secondary spreading could be considered an 
advantage or disadvantage depending upon the purpose and 
possible activity of the inserted foreign gene. Generally, the 
Food and Drug Administration (FDA) and some others con-
sider the possibility of such continuous spreading to be unac-
ceptable. However, such spreading may be desirable in certain 
treatment situations such as in metastatic cancer and AIDS. 
In any case, secondary spreading would likely be limited, due 
to anti-AAV antibodies, in all but the most severely immune-
compromised individuals. Furthermore, the large wild-type 
vectors will be at a packaging disadvantage when cells are 
co-infected with true wild-type AAV or with large wild-type-
plus vectors with deletion mutations within the foreign gene 
(wild-type D.I.s). As AAV has not been demonstrated to be 
the etiologic agent of any disease, the FDA may ultimately 
allow the clinical use of such wild-type AAV vectors. 
Although this study directly addresses the packaging ca-
pacity of the AAV virion, the large genomes which we have 
used may not represent the packaging efficiency of all re-
combinant AAV vectors. Equivalently large 'gutted' recombi-
nant AAV genomes, based on only the AAV TRs may have a 
slightly different packaging capacity. Such large minimal AAV 
vectors may not to be packaged as efficiently as the vectors of 
this study as wild-type AAV is preferentially packaged over 
recombinant AAV of equal size (Hermonat, unpublished). 
This difference may be due to the elimination of DNA sequen-
ces (e.g. secondary structure or 'minor' packaging sequences) 
located between the AAV terminal repeats (TR). Further-
more, interaction, or lack of interaction, of the inserted for-
eign DNA with the AAV encoded Rep78 protein may also 
alter the efficiency of packaging. The AAV encoded Rep78 
protein been shown to interact both with the AAV capsid 
proteins [23] and AAV TR DNA [24], as well as multiple 
sequences within human chromosomal DNA [19,25]. Thus, 
the specific foreign DNA which is inserted into the AAV 
vector will likely affect packaging, due to differing interactions 
with the packaging machinery. Extending this idea further, it 
may be that every foreign gene inserted into AAV may result 
in a vector with a somewhat different packaging capacity. 
Another possible use of such large wild-type-plus AAV ge-
nomes is as complementors for fully defective AAV vectors. 
Such complementors can be delivered by virus infection and, 
thus, be easily introduced into 100% of the cells used to pro-
duce virus. Virus infection is likely be superior to synthetic 
techniques for introducing DNA into tissue culture producer 
cells. When large wild-type AAV complementor virus are used 
in conjunction with AAV vector virus, allowing for the intro-
duction of both into all cells, this technique is likely to be a 
very good system, if not the best, for producing the highest 
titers of recombinant AAV virus particles without concentra-
tion. 
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